Patents Examined by Sun Jae Y Loewe
  • Patent number: 8138367
    Abstract: The present invention provides a process for the production of an aromatic carbonate, comprising the steps of: continuously feeding an aliphatic carbonate represented by following general formula (1) as a starting material, an aromatic monohydroxy compound represented by following general formula (2) as a reactant, and a metal-containing catalyst into a stage above the bottom of a first multi-stage distillation column so as to bring about reaction; continuously withdrawing from the reaction system in a gaseous form a low boiling point component containing an alcohol by-produced in the reaction; and continuously withdrawing from a lower portion of the column in a liquid form an aromatic carbonate represented by following general formula (3) obtained from the starting material and the reactant Ar1OH??(2) wherein R1 in general formulae (1) and (2) represents an aliphatic group having 4 to 6 carbon atoms, and Ar1 represents an aromatic group having 5 to 30 carbon atoms wherein R2 and Ar2 in general formu
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: March 20, 2012
    Assignee: Asahi Kasei Chemicals Corporation
    Inventor: Nobuhisa Miyake
  • Patent number: 8013004
    Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or (II): including a stereoisomer thereof, a tautomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Q is selected from N, O, and S; Y is aryl or heteroaryl; Z is H, C2-6alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, or alkoxy; and A, B, R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: September 6, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: T. G. Murali Dhar, Hai-Yun Xiao, Bingwei Yang
  • Patent number: 8003625
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: August 23, 2011
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Patent number: 7977372
    Abstract: Compounds of formula are HDAC inhibitors. These compounds are useful for the treatment of diseases such as cancer in humans or animals.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: July 12, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Guozhi Tang, Jason Christopher Wong, Xihan Wu, Zhenshan Zhang
  • Patent number: 7977322
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: July 12, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sara Hadida Ruah, Peter Grootenhuis, Mark Miller, Matthew Hamilton
  • Patent number: 7973078
    Abstract: A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: July 5, 2011
    Assignee: Astellas Pharma Inc.
    Inventors: Hideki Kubota, Susumu Toda, Issei Tsukamoto, Yuta Fukuda, Ryutaro Wakayama, Kazuki Ono, Toru Watanabe, Hidenori Azami
  • Patent number: 7968582
    Abstract: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: June 28, 2011
    Assignee: Laborotorios Del Dr. Esteve, S.A.
    Inventor: Rosa Cuberes
  • Patent number: 7968575
    Abstract: Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, pharmaceutical compositions and medical devices containing such compounds and methods utilizing such compounds in the treatment of various medical conditions.
    Type: Grant
    Filed: May 5, 2005
    Date of Patent: June 28, 2011
    Assignee: Renopharm Ltd.
    Inventors: Peter Assaf, Elham Gazaleen-Mariee, Michael Naveh
  • Patent number: 7964646
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: June 21, 2011
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Jr., Laura L. Rokosz, Gaifa Lai
  • Patent number: 7964627
    Abstract: The present invention relates to novel amino arylsulfonamide compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them: The present invention also relates to a process for the preparation of above said novel compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The compounds of the invention are useful in the treatment of various disorders that are related to 5-HT6 receptor functions. Specifically, the compounds of this invention are also useful in the treatment of various CNS disorders, hematological disorders, eating disorders, obesity, anxiety, depression, diseases associated with pain, respiratory diseases, gastrointestinal, cardiovascular diseases and cancer.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: June 21, 2011
    Assignee: Suven Life Sciences Limited
    Inventors: Nirogi Venkata Satya Ramakrishna, Rama Sastri Kambhampati, Anil Karbhari Shinde, Nagaraj Vishwottam Kandikere, Venkateswarlu Jasti
  • Patent number: 7960418
    Abstract: The present invention provides new class of 4?-[4?-(1?,3?-benzothiazole-2?-yl)anilino]podophyllotoxin analogues having the structural formula as follows (4). Where R?H or CH3; R1?H, halogen, CH3 and R2?H, halogen, OCH3. The present invention also provides a process for the preparation of new 4?-[4?-(1?, 3?-benzothiazole-2?-yl)anilino]podophyllotoxin analogues as useful anticancer agents. More particularly, it provides a process for the preparation of 4?-[4?-(1?,3?-benzothiazole-2?-yl)anilino] derivatives of podophyllotoxin. The process for the synthesis of new podophyllotoxin analogues as anticancer agents produces the novel and stereo-selective derivatives of the podophyllotoxin in good yields, where in the key step for the synthesis of these analogues is by direct nucleophilic substitution of C-4?-iodo intermediates.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: June 14, 2011
    Assignee: Council of Scientific & Industrial Research
    Inventors: Kamal Ahmed, Ashwini Kumar Banala
  • Patent number: 7960365
    Abstract: The invention provides for compounds having the structure according to the formula I wherein: X is a carbon or nitrogen atom; Ar is phenyl or heteroaromatic ring; R1 is hydrogen, halogen, CN or (1C-4C)alkyl; R2 is hydrogen, halogen or optionally fluorinated (1C-3C)alkoxy; R3 and R5 are independently hydrogen, optionally halogenated (1C-4C)alkyl, optionally halogenated (1C-4C)alkoxy, optionally halogenated aryl(1C-4C)alkoxy, optionally halogenated (1C-4C)alkenyl or hydroxylmethyl; R4 is hydrogen, halogen, optionally halogenated (1C-4C)alkoxy or optionally halogenated aryl(1C-4C)alkoxy; R6 is hydrogen, benzyl, optionally substituted with one or more halogens or (1C-4C)alkyl, or R6 is optionally halogenated (1C-4C)alkyl; each R7 independently is hydrogen, halogen, optionally halogenated (1C-4C)alkyl or optionally halogenated (1C-4C)alkoxy and pharmaceutically suitable acid addition salts thereof for use as glucocorticoid receptor modulators, in particular for treatment of central nervous system disorders.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: June 14, 2011
    Assignee: N.V. Organon
    Inventors: Niall Morton Hamilton, Simon James Anthony Grove, Michael John Kiczun, John Richard Morphy, Brad Sherborne, Peter Thomas Albert Littlewood, Angus Richard Brown, Celia Kingsbury, Michael Ohhlmeyer, Koc-Kan Ho, Steven G. Kultgen
  • Patent number: 7956083
    Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: June 7, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson
  • Patent number: 7956077
    Abstract: The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with cyclohexylmethoxy substituents and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of formula I wherein the various substituent R-groups are more specifically defined herein.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: June 7, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heiner Glombik, Christian Stapper, Eugen Falk, Stefanie Keil, Hans-Ludwig Schaefer, Wolfgang Wendler, Stephanie Knieps
  • Patent number: 7951829
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: May 31, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Wells, Derek A. Beauchamp
  • Patent number: 7951827
    Abstract: Novel dicationic 3,5-diphenylisoxazole compounds are described. Synthetic routes to these novel compounds are provided. Several of the compounds displayed in vitro activity versus Trypanosoma brucei brucei and Plasmodium falciparum comparable to that of furamidine. A majority of the novel compounds also were less toxic to VERO cells than furamidine.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: May 31, 2011
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Richard R. Tidwell, Svetlana M. Bakunova, Stanislav Bakunov, Donald A. Patrick
  • Patent number: 7947720
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: May 24, 2011
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Jr., Laura L. Rokosz
  • Patent number: 7947664
    Abstract: A compound having the structure wherein R is an angiotensin receptor antagonist active group, Y is selected from the group consisting of and 2) —C(R1H)OC(O)X((CR12R13)—(CHR10)m—(CH2)n—Zp—(CH2)q—(CHR11)r—(CR16R17))—R5; Z is —O— or —(CR14R15)—; m, n, p, q, and r are independently selected from the group consisting of 0 and 1; X is —O— or —(CR18R19)—; R1 is selected from the group consisting of hydrogen, C1-4 alkyl, aryl and C1-4 alkylaryl; R5 is —O—N?N(O)—NR3R4; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: May 24, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Christopher Franklin, Brent R. Whitehead
  • Patent number: 7947728
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: May 24, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David Robert Bolin, Matthew Michael Hamilton, Lee Apostle McDermott, Lin Yi
  • Patent number: 7943651
    Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions comprising the compounds and the use of the compounds for the manufacture of a medicament, particularly for the treatment of inflammation and/or allergic conditions.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: May 17, 2011
    Assignee: Glaxo Group Limited
    Inventors: Keith Biggadike, Anthony William James Cooper, David House, Iain McFarlane McLay